New Phase I/II trial of MV-CHIKV for chikungunya begins enrolment

A new Phase I/II clinical trial of MV-CHIKV sponsored by the National Institutes of Health ’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of the chikungunya virus has begun enrolling healthy adult subjects at…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news